Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Celgene

    Tag: Celgene

    You Searched For "Celgene"
    More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs

    More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs

    Medical Dialogues Bureau2 Jan 2020 2:48 PM IST
    New Delhi: Drugmakers including Bristol-Myers Squibb Co (BMY.N), Gilead Sciences Inc (GILD.O), and Biogen Inc (BIIB.O) hiked U.S. list prices on more...
    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    BeiGene gets USFDA approval for lymphoma drug Brukinsa

    Medical Dialogues Bureau17 Nov 2019 9:20 AM IST
    BeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
    Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

    Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

    Medical Dialogues Bureau28 July 2019 9:17 AM IST
    Sales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Abbvie finalizes deal to buy Botox maker Allergan for $63 billion

    Medical Dialogues Bureau26 Jun 2019 10:00 AM IST
    A note from Moody's affirmed Abbvie's debt rating, saying a plan to reduce debt through existing blockbusters like AbbVie's Humira and Imbruvica and...
    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene

    Medical Dialogues Bureau26 Jun 2019 9:00 AM IST
    Bristol-Myers announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology...
    Panacea Biotec gets USFDA nod for chemotherapy drug Azacitidine

    Panacea Biotec gets USFDA nod for chemotherapy drug Azacitidine

    Farhat Nasim22 May 2019 9:45 AM IST
    Azacitidine is a chemotherapy drug used to treat myelodysplastic syndromes (MDS) with annual sales of about USD 110 million in US markets as per IQVIA...
    Eli Lilly to acquire Loxo Oncology for $8 billion

    Eli Lilly to acquire Loxo Oncology for $8 billion

    Medical Dialogues Bureau8 Jan 2019 12:09 PM IST
    Washington: -Pharmaceutical giant Eli Lilly will acquire cancer treatment specialist Loxo Oncology in a cash deal valued at around $8 billion, the...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok